Product Pathways - Lymphocyte Signaling
Galectin-3/LGALS3 Antibody #12733
|12733S||100 µl (10 western blots)||---||In Stock||---|
|12733||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Mouse, Rat||Endogenous||28||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Specificity / Sensitivity
Galectin-3/LGALS3 antibody recognizes endogenous levels of total galectin-3/LGALS3 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human galectin-3/LGALS3 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Galectins are a family of β-galactose binding proteins that are characterized by an affinity for poly-N-acetyllactosamine-enriched glycoconjugates and a carbohydrate-binding site (1,2). Members of the galectin family have been implicated in a variety of biological functions including cell adhesion (3), growth regulation (4), cytokine production (5), T-cell apoptosis (6), and immune responses (7).
Galectin-3/LGALS3 is involved in several diverse biological functions. Galectin-3/LGALS3 binds IgE (8). Galectin-3/LGALS3 is an unusual protein in that can be found both extracellularly and intracellularly. Intracellularly, galectin-3/LGALS3 can localize to the cytoplasm, nucleus, or both, depending on cell type and experimental conditions. Nuclear galectin-3/LGALS3 has been identified as a pre-mRNA splicing factor (9). Galectin-3/LGALS3 production has been shown to increase during inflammation and in obesity, and the protein itself can have an inflammatory effect under certain conditions (10). Galectin-3/LGALS3 forms a complex with α3, β1 integrin to act as a surface receptor on endothelial cells for the NG2 proteoglycan, which triggers cell motility and angiogenesis (11). In addition to these functions, galectin-3/LGALS3 is also a required factor for the terminal differentiation of epithelial cells (12).
- Barondes, S.H. et al. (1994) Cell 76, 597-8.
- Barondes, S.H. et al. (1994) J Biol Chem 269, 20807-10.
- Offner, H. et al. (1990) J Neuroimmunol 28, 177-84.
- Wells, V. and Mallucci, L. (1991) Cell 64, 91-7.
- Filer, A. et al. (2009) Arthritis Rheum 60, 1604-14.
- Perillo, N.L. et al. (1995) Nature 378, 736-9.
- Cooper, D.N. et al. (1991) J Cell Biol 115, 1437-48.
- Platzer, B. et al. (2011) Immunol Lett 141, 36-44.
- Haudek, K.C. et al. (2010) Biochim Biophys Acta 1800, 181-9.
- Pang, J. et al. (2013) PLoS One 8, e57915.
- Fukushi, J. et al. (2004) Mol Biol Cell 15, 3580-90.
- Hikita, C. et al. (2000) J Cell Biol 151, 1235-46.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.